The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

Histone deacetylases (HDACs) are expressed at increased levels in cells of various
malignancies, and the use of HDAC inhibitors has improved outcomes in patients with …

Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and
activities of transcriptional factors involved in both cancer initiation and progression through …

Cancer drug development has moved from conventional cytotoxic chemotherapeutics to a
more mechanism-based targeted approach towards the common goal of tumour growth …

Histone deacetylase (HDAC) inhibitors are a new group of anticancer agents that have a
potential role in the regulation of gene expression, induction of cell death, apoptosis and cell …

Histone deacetylase (HDAC) inhibitors are emerging as promising anticancer drugs.
Because aberrant activity and expression of HDACs have been implicated in various cancer …

Histone deacetylases (HDAC) play a key role in regulating gene expression by
deacetylating histones. Some HDAC isoforms can also modulate the function of nonhistone …

Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential
as anticancer drugs. The rationale for developing HDAC inhibitors (and other chromatin …

It is now 30 years since the first report of a potent zinc-dependent histone deacetylase
(HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory …

Histones are a family of nuclear proteins that interact with DNA, resulting in DNA being
wrapped around a core of histone octamer within the nucleosome. Acetylation/deacetylation …